PriceTargets.com logo

Progyny - PGNY Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $48.30
  • Forecasted Upside: 48.16%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$32.60 As of 04/24/2024 01:00 AM ET
▲ +0.2 (0.62%)

This chart shows the closing price for PGNY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Progyny Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PGNY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PGNY

Analyst Price Target is $48.30
▲ +48.16% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Progyny in the last 3 months. The average price target is $48.30, with a high forecast of $57.00 and a low forecast of $43.00. The average price target represents a 48.16% upside from the last price of $32.60.

This chart shows the closing price for PGNY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 10 polled investment analysts is to buy stock in Progyny. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/17/2024Truist FinancialReiterated RatingBuy ➝ Buy$46.00N/A
2/28/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$48.00Low
2/28/2024Truist FinancialLower TargetBuy ➝ Buy$47.00 ➝ $46.00Low
2/28/2024KeyCorpLower TargetOverweight ➝ Overweight$45.00 ➝ $43.00Low
2/26/2024Leerink PartnrsReiterated RatingOutperformLow
2/26/2024SVB LeerinkInitiated CoverageOutperform$49.00Low
1/3/2024BarclaysInitiated CoverageOverweight$48.00Low
11/8/2023Truist FinancialLower TargetBuy ➝ Buy$52.00 ➝ $47.00Low
11/8/2023KeyCorpLower TargetOverweight ➝ Overweight$50.00 ➝ $45.00Low
10/9/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$58.00 ➝ $57.00Low
9/27/2023Canaccord Genuity GroupInitiated CoverageBuy$46.00Low
9/27/2023Canaccord Genuity GroupInitiated CoverageBuy$46.00Low
9/14/2023Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$45.00 ➝ $48.00Low
8/11/2023Truist FinancialBoost TargetBuy ➝ Buy$48.00 ➝ $52.00Low
8/4/2023KeyCorpBoost TargetOverweight ➝ Overweight$45.00 ➝ $50.00Low
5/22/2023BTIG ResearchInitiated CoverageBuy$50.00Low
5/9/2023Bank of AmericaBoost Target$48.00 ➝ $50.00Low
5/9/2023Cantor FitzgeraldBoost Target$44.00 ➝ $45.00Low
4/20/2023Cantor FitzgeraldInitiated CoverageOverweight$44.00Low
1/5/2023SVB LeerinkReiterated RatingOutperform ➝ Market Perform$59.00 ➝ $34.00Low
12/19/2022KeyCorpLower TargetOverweight$55.00 ➝ $45.00Low
11/18/2022JPMorgan Chase & Co.Lower TargetOverweight$78.00 ➝ $62.00Low
9/15/2022KeyCorpInitiated CoverageOverweight$55.00Low
9/7/2022Truist FinancialInitiated CoverageBuy$56.00Low
12/1/2021Jefferies Financial GroupInitiated CoverageBuy$60.00High
11/22/2021CitigroupDowngradeBuy ➝ Neutral$60.00 ➝ $64.00High
10/22/2021JPMorgan Chase & Co.Boost TargetOverweight$65.00 ➝ $79.00Medium
9/30/2021Berenberg BankInitiated CoverageBuy$81.00Low
9/28/2021BarclaysBoost TargetTop Pick ➝ Overweight$72.00 ➝ $80.00High
8/25/2021BarclaysBoost TargetOverweight$64.00 ➝ $72.00High
8/12/2021BarclaysInitiated CoverageOverweight$64.00Low
8/6/2021SVB LeerinkLower TargetOutperform$64.00 ➝ $59.00High
6/2/2021GuggenheimDowngradeBuy ➝ NeutralLow
5/7/2021SVB LeerinkBoost TargetOutperform$58.00 ➝ $64.00High
4/29/2021JPMorgan Chase & Co.Initiated CoverageOverweightLow
3/16/2021Bank of AmericaUpgradeNeutral ➝ BuyHigh
3/10/2021Bank of AmericaUpgradeNeutral ➝ Buy$53.00High
11/25/2020Bank of AmericaBoost TargetNeutral$30.00 ➝ $35.00Low
11/6/2020SVB LeerinkBoost TargetOutperform$44.00 ➝ $50.00High
8/24/2020JPMorgan Chase & Co.Boost TargetOverweight$30.00 ➝ $35.00High
8/6/2020Piper SandlerBoost TargetOverweight$32.00 ➝ $33.00Medium
8/6/2020SVB LeerinkBoost TargetOutperform$35.00 ➝ $44.00Medium
8/6/2020CitigroupBoost TargetBuy$28.00 ➝ $32.00Medium
7/27/2020Bank of AmericaBoost TargetNeutral$26.00 ➝ $28.00High
7/1/2020SVB LeerinkInitiated CoverageOutperform$35.00High
6/2/2020GuggenheimInitiated CoverageBuy$30.00Low
5/13/2020CitigroupLower TargetBuy$29.00 ➝ $28.00High
3/10/2020CitigroupLower TargetBuy$30.00 ➝ $29.00Medium
11/27/2019JPMorgan Chase & Co.Initiated CoverageOverweight$26.00Low
11/27/2019SVB LeerinkInitiated CoverageOutperform$28.00Low
11/27/2019CitigroupInitiated CoverageBuy$30.00Low
11/27/2019Piper Sandler CompaniesInitiated CoverageOverweight$33.00Low
11/19/2019SVB LeerinkInitiated CoverageOutperform$28.00High
11/19/2019JPMorgan Chase & Co.Initiated CoverageOverweight$26.00 ➝ $26.00High
11/19/2019CitigroupInitiated CoverageBuy$30.00 ➝ $30.00High
11/19/2019Piper Sandler CompaniesInitiated CoverageOverweight$33.00 ➝ $33.00High
11/19/2019The Goldman Sachs GroupInitiated CoverageBuy$33.00High
(Data available from 4/25/2019 forward)

News Sentiment Rating

1.09 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 11 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 5 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 8 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 17 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 16 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 17 very positive mentions
  • 20 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 19 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 19 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Progyny logo
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Read More

Today's Range

Now: $32.60
Low: $32.00
High: $32.61

50 Day Range

MA: $36.20
Low: $31.88
High: $41.38

52 Week Range

Now: $32.60
Low: $29.44
High: $44.95

Volume

759,132 shs

Average Volume

786,495 shs

Market Capitalization

$3.13 billion

P/E Ratio

52.58

Dividend Yield

N/A

Beta

1.48

Frequently Asked Questions

What sell-side analysts currently cover shares of Progyny?

The following Wall Street sell-side analysts have issued research reports on Progyny in the last year: Bank of America Co., Barclays PLC, BTIG Research, Canaccord Genuity Group Inc., Cantor Fitzgerald, JPMorgan Chase & Co., KeyCorp, Leerink Partnrs, SVB Leerink LLC, and Truist Financial Co..
View the latest analyst ratings for PGNY.

What is the current price target for Progyny?

10 Wall Street analysts have set twelve-month price targets for Progyny in the last year. Their average twelve-month price target is $48.30, suggesting a possible upside of 48.2%. JPMorgan Chase & Co. has the highest price target set, predicting PGNY will reach $57.00 in the next twelve months. KeyCorp has the lowest price target set, forecasting a price of $43.00 for Progyny in the next year.
View the latest price targets for PGNY.

What is the current consensus analyst rating for Progyny?

Progyny currently has 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PGNY will outperform the market and that investors should add to their positions of Progyny.
View the latest ratings for PGNY.

What other companies compete with Progyny?

Other companies that are similar to Progyny include Sotera Health, agilon health, Tivity Health, American Renal Associates and DaVita. Learn More about companies similar to Progyny.

How do I contact Progyny's investor relations team?

Progyny's physical mailing address is 1359 BROADWAY, NEW YORK NY, 10018. The company's listed phone number is 212-888-3124 and its investor relations email address is [email protected]. The official website for Progyny is www.progyny.com. Learn More about contacing Progyny investor relations.